Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Amgen (NQ: AMGN )

280.07 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Nov 27, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Amgen

< Previous 1 2
...
28 29 30 31 32 33 34 35 36
...
47 48 Next >
Dogs Of The Dow: A Leading Strategy In 2022
At that time the Dow Dogs strategy had a positive year-to-date return versus the negative return of the Dow Jones Industrial Average Index and the S&P 500 Index. 
Via Talk Markets
Could Amgen Continue To Soar In This Bear Market?
Amgen did a mini pull back then broke out on 24 Oct and committed above $260. According to the Wyckoff trading method, there is no immediate threatening supply hence the price could continue to climb... 
Via Talk Markets
This Company Is Racing Toward Providing Comfort And Safety To Millions Of Psoriasis Sufferers
The competition between pharmaceutical company trials to help the 2% to 3% of the population suffering from chronic psoriasis is heating up.   
Via Benzinga
Dissecting The Dow Jones Industrial Average: Half Empty Or Half Full?
The Dow Jones Industrial Average is a leading index comprised of 30 stocks. Consequently, it has long been considered a great proxy for the stock market at large. 
Via Talk Markets
Will Chart Analysts Notice Bad Omen on Amgen's Chart
If history is any guide, there may be trouble ahead for shares of Amgen (NASDAQ:AMGN). A so-called "death cross" has formed on its chart and, not surprisingly, this could be bearish for the stock. 
Via Benzinga
Is Amgen Stock a Buy Now?
A recent analyst upgrade has boosted the stock. 
Via The Motley Fool
Expert Ratings for Amgen
Amgen (NASDAQ:AMGN) has observed the following analyst ratings within the last quarter: 
Via Benzinga
Why Amgen Is Up More Than 6% Today
An upgrade highlights one of the more philosophical reasons you want to bet on this biopharma name right now. 
Via The Motley Fool
Cytokinetics CEO: Why It's OK Not Being An Overnight Success
The company hopes to come out next year with at least one heart-failure drug. 
Via Investor's Business Daily
Biosimilars Are Revolutionizing Healthcare: Is This Industry Leader a Buy?
Biosimilars are bringing down prescription drug costs without sacrificing quality. 
Via The Motley Fool
Here's How Much You Would Have Made Owning Amgen Stock In The Last 20 Years
Amgen (NASDAQ:AMGN) has outperformed the market over the past 20 years by 1.09% on an annualized basis producing an average annual return of 8.55%. Currently, Amgen has a market capitalization of... 
Via Benzinga
CRISPR Stocks: Will Concerns Over Risk Inhibit Gene-Editing Cures?
Despite enthusiasm in some camps, the risk of potential cures clouds market projections. 
Via Investor's Business Daily
Merck Nears Breakout Point After October Surprise Good News
Dow component Merck is within 2% of an all-time high after rallying 7.30% in the past month. It got a boost from news about two new treatments. 
Via MarketBeat
Topics Stocks
Exposures US Equities
10 Health Care Stocks Whale Activity In Today's Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
2 Top Healthcare Stocks to Buy for the Long Haul
These biotech companies have a long ramp of revenue growth ahead. 
Via The Motley Fool
MarketBeat: Week in Review 10/10-10/14
A volatile week is ending with the market moving lower. Here are some of the stories the MarketBeat analysts were covering this week. 
Via MarketBeat
Exposures COVID-19
Replimune Gets 33% Price Target Bump Ahead Of Upcoming Readouts. Analyst Lists The Catalysts
Via Benzinga
Amgen Shares Leap Higher On Upbeat Outlook For Obesity Treatment
Shares of Amgen soared 5.72% Tuesday and added to those gains Wednesday. The gap-up followed a Morgan Stanley upgrade and increase to the price target. 
Via MarketBeat
Dividend Income Update September 2022
With the start of the final quarter of 2022, it’s time to take a look back at my previous month of dividend income. 
Via Talk Markets
Amgen Stock Shows Market Leadership With Jump To 90 RS Rating
On Wednesday, Amgen stock hit a key technical milestone, with its Relative Strength Rating upgraded to 90, a rise from 78 the day before. 
Via Investor's Business Daily
What 6 Analyst Ratings Have To Say About Amgen
Over the past 3 months, 6 analysts have published their opinion on Amgen (NASDAQ:AMGN) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's... 
Via Benzinga
4 Biotech Stocks With Huge Incoming Catalysts
All four of these drugmakers are expecting important FDA approval decisions over the next few months. 
Via The Motley Fool
Biotech Stocks Well-Positioned For The Fourth Quarter
The path of interest rates is clearer for 2022 and the FED is closer to a pause early next year as it calibrates its response from a hammer approach so far. 
Via Talk Markets
Analyst Ratings for Amgen
Over the past 3 months, 5 analysts have published their opinion on Amgen (NASDAQ:AMGN) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's... 
Via Benzinga
Amgen, The Big Name You Need To Know Going Up Against Novo, Lilly In Obesity
One analyst says a coming-from-behind obesity player could differentiate itself. 
Via Investor's Business Daily
A Congressman Just Sold JPMorgan Stock Ahead Of Earnings: See Two Dividend Stocks He Is Also Trading
Congressman Earl Blumenauer (D-Ore.) has served as the U.S. Representative for Oregon's 3rd congressional district since 1996. 
Via Benzinga
DICE Therapeutics, Amgen And Some Other Big Stocks Moving Higher On Tuesday
U.S. stocks traded mostly lower, with the Nasdaq dropping more than 100 points on Tuesday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 11, 2022
Upgrades 
Via Benzinga
Apple To $155? Plus Morgan Stanley Cuts Price Target On Zoom Video
Barclays cut the price target on Apple Inc. (NASDAQ: AAPL) from $169 to $155. Apple shares fell 0.4% to $139.93 in pre-market trading. 
Via Benzinga
US Buys $290M Anti-Radiation Drugs After Putin Ups Nuclear Threats
President Joe Biden has warned that the country may face nuclear Armageddon for the first time since the Cuban Missile Crisis of 1962. 
Via Benzinga
< Previous 1 2
...
28 29 30 31 32 33 34 35 36
...
47 48 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback